Está la IA revolucionando el desarrollo de fármacos

Artificial intelligence is transforming drug discovery by shifting from artisanal processes to automated systems that generate massive volumes of biochemical data. This revolution enables the training of algorithms to identify molecular patterns and design therapeutic candidates with greater precision, significantly reducing the time and costs associated with traditional development, which has historically been slow, expensive, and characterized by high failure rates. The relevance to open data lies in the critical need for accurate, structured scientific data to feed these models. Leading companies are building industrial-scale infrastructures to generate this information, while others opt for computational approaches that minimize dependence on large experimental datasets. The quality and accessibility of these data are crucial to avoiding errors and validating algorithmic predictions before proceeding to clinical trials. The current model is characterized by collaboration between technology startups and major pharmaceutical companies, where startups accelerate preclinical phases using AI, while large firms take on the costly human clinical trials. The ultimate success of this convergence will depend on demonstrating a real increase in the success rate of treatments and the efficacy of the resulting drugs, thereby establishing artificial intelligence as an indispensable tool in modern biomedical research.

Source: diario.mx
Published on 2024-06-19

Elementos asociados a la memoria de las radios patrimoniales en el estado Cojedes »

Open Data

Related news